William James Antonisamy

Dr. William James Antonisamy

Medicinal and Biological Chemistry, University of Toledo, Toledo, Ohio, USA
orcid
Postdoctoral Research Associate

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2022 in Neurochemistry International
Verified
Journal Article
Closed access
FSFaheem Shehjar
Faheem Shehjar
BMBriana Maktabi
Briana Maktabi
ZRZainab A. Rahman
Zainab A. Rahman
GBGhaith A. Bahader
Ghaith A. Bahader
William James AntonisamyWilliam James Antonisamy
William James Antonisamy
Zahoor A. ShahZahoor A. Shah
Zahoor A. Shah

17 April 2025 in Cells
Verified
Journal Article
Open access
PDF file
AAAseel Yousef Altahrawi
Aseel Yousef Altahrawi
William James AntonisamyWilliam James Antonisamy
William James Antonisamy
Zahoor A. ShahZahoor A. Shah
Zahoor A. Shah
Vascular dementia (VaD) is a heterogeneous group of brain disorders caused by cerebrovascular pathologies and the second most common cause of dementia, accounting for over 20% of cases and posing an important global health concern. VaD can be caused by cerebral infarction or injury in critical brain regions, including the speech area of the dominant hemisphere or arcuate fasciculus of the dominant hemisphere, leading to notable cognitive impairment. Although the exact causes of dementia remain multifactorial and complex, oxidative stress (reactive oxygen species), neuroinflammation (TNFα, IL-6, and IL-1β), and inflammasomes are considered central mechanisms in its pathology. These conditions contribute to neuronal damage, synaptic dysfunction, and cognitive decline. Thus, antioxidants and anti-inflammatory agents have emerged as potential therapeutic targets in dementia. Recent studies emphasize that cerebrovascular disease plays a dual role: first, as a primary cause of cognitive impairment and then as a contributor to the manifestation of dementia driven by other factors, such as Alzheimer’s disease and other neurodegenerative conditions. This comprehensive review of VaD focuses on molecular mechanisms and their consequences. We provided up-to-date knowledge about epidemiology, pathophysiological mechanisms, and current therapeutic approaches for VaD.

1 January 2014 in Bioresource Technology
Verified
Journal Article
Closed access
William James AntonisamyWilliam James Antonisamy
William James Antonisamy
VNVasanthi Nachiappan
Vasanthi Nachiappan

1 January 2018 in Journal of Lipid Research
Verified
Journal Article
Open access
SISara Irani
Sara Irani
JIJahangir Iqbal
Jahangir Iqbal
William James AntonisamyWilliam James Antonisamy
William James Antonisamy
LILaraib Ijaz
Laraib Ijaz
MHM. Mahmood Hussain
M. Mahmood Hussain
High plasma cholesterol levels are found in several metabolic disorders and their reductions are advocated to reduce the risk of atherosclerosis. A way to lower plasma lipids is to curtail lipoprotein production; however, this is associated with steatosis. We previously showed that microRNA (miR)-30c lowers diet-induced hypercholesterolemia and atherosclerosis in C57BL/6J and Apoe-/- mice. Here, we tested the effect of miR-30c on plasma lipids, transaminases, and hepatic lipids in different mouse models. Hepatic delivery of miR-30c to chow-fed leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) hypercholesterolemic and hyperglycemic mice reduced cholesterol in total plasma and VLDL/LDL by ∼28% and ∼25%, respectively, without affecting triglyceride and glucose levels. And these mice had lower plasma transaminases and creatine kinase activities than controls. Moreover, miR-30c significantly lowered plasma cholesterol and atherosclerosis in Western diet-fed Ldlr-/- mice with no effect on plasma triglyceride, glucose, and transaminases. In these studies, hepatic lipids were similar in control and miR-30c-injected mice. Mechanistic studies showed that miR-30c reduced hepatic microsomal triglyceride transfer protein activity and lipid synthesis. Thus miR-30c reduced plasma cholesterol in several diet-induced and diabetic hypercholesterolemic mice. We speculate that miR-30c may be beneficial in lowering plasma cholesterol in different metabolic disorders independent of the origin of hypercholesterolemia.

Verified
Journal Article
Open access
PDF file
SHSyed A.M Hasan
Syed A.M Hasan
William James AntonisamyWilliam James Antonisamy
William James Antonisamy
FFFarzeen M. Fazili
Farzeen M. Fazili
STSamiha Tarabishi
Samiha Tarabishi
NSNamir M. Sheikh
Namir M. Sheikh
Zahoor A. ShahZahoor A. Shah
Zahoor A. Shah
Endoplasmic reticulum (ER) stress is a detrimental cellular phenomenon in the cells and is activated by the accumulation of unfolded or misfolded proteins in the ER. The unfolded protein accumulation activates the unfolded protein response (UPR), an adaptive mechanism designed to mitigate cellular stress by enhancing the ER’s protein-folding capacity and protecting cells from apoptotic stimuli in neuroinflammation and neurodegenerative diseases. However, chronic ER stress and prolonged activation of the UPR can have adverse effects, including the activation of pro-apoptotic and inflammatory signaling pathways, which contribute to the development and progression of neurodegenerative disorders. Neurodegenerative diseases are complex and devastating conditions with underlying pathogenesis that are not fully understood. Genetic mutations leading to the accumulation of misfolded or phosphorylated tau proteins and amyloid-beta in the ER can induce ER stress, resulting in neuroinflammation and neuronal death. Several studies have reported the involvement of increased ER stress and UPR signaling proteins in the pathogenesis and progression of neurodegenerative diseases. Thus, inhibiting ER stress and neuroinflammation and targeting their associated signaling pathways represent a significant area of research interest. This review discusses the critical signaling molecules involved in ER stress, their mechanisms in the progression of neurodegenerative diseases, and the latest developments in the available ER stress inhibitors. Despite the extensive development of ER stress inhibitors over the years, only a limited number have been approved as pharmaceutical drugs. There remains a critical need for effective ER stress inhibitors to provide efficient treatments for neurodegenerative diseases, including Alzheimer’s disease.

28 October 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EKEndri Karaj
Endri Karaj
SSShaimaa H. Sindi
Shaimaa H. Sindi
NKNishanth Kuganesan
Nishanth Kuganesan
RKRadhika A. Koranne
Radhika A. Koranne
JKJoseph R. Knoff
Joseph R. Knoff
LTL. M. Viranga Tillekeratne
L. M. Viranga Tillekeratne